Telomerase is a ribonucleoprotein that is also present in cancer cells. By suppressing these telomerase inhibitors, medications are able to address forms of cancers. The technology platform owned by Geron Corporation aims to develop therapeutic products that are intended for cancer.
By applying their expertise in telomere biology and telomerase, the company is able to create novelty products that would combat cancer at the cellular level. By attacking the DNA structure of these cancer cells, they are able to lessen the instances of recurrence of the deadly disease. The company has several products that are under various clinical trials. Some of these developments were created through the partnership of the company with other biopharmaceutical ventures.
The business is headquartered in Menlo Park, California and was started by Michael D. West, a gerontologist. It was in 1990 that the company started and now publicly trades on the NASDAQ, using the symbol GERN.